Asthma drug trial halted midway: what it means for patients

NCT ID NCT05813288

Disease control Sponsor: Areteia Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a daily pill called dexpramipexole in 654 people with severe eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. The goal was to see if the drug could reduce severe asthma attacks over a year. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: dexpramipexole
What this could lead to: If successful, this could provide a new oral treatment option to reduce severe asthma attacks in people with eosinophilic asthma.
What could go wrong: The trial was terminated, so results may be incomplete. It is unclear if dexpramipexole works better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

654 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed informed consent form and assent form, as appropriate. 2. Male or female ≥12 years of age at Screening Visit 1. Asthma-related criteria 3. Documented physician diagnosis of asthma for ≥12 months prior to Screening Visit 1. 4. Eosinophil count of ≥0.30x10⁹/L at Screening Visit 1. If the initial value is between 0.250x10⁹/L to 0.299x10⁹/L, then this may be repeated once at an unscheduled visit (prior to Screening Visit 2). 5. Treatment of asthma, participants must satisfy all the below (items a to c): 1. Participants who have received asthma controller medication with medium or high dose inhaled corticosteroids (ICS ≥500 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021) on a regular basis for at least 12 months prior to Screening Visit 1. 2. Documented treatment with a stable dose of either medium or high dose ICS for at least 3 months prior to Visit 1. The ICS may be contained within an ICS/long-acting β2 agonist (LABA) combination product. Daily oral corticosteroids are an allowed concomitant medication; participants on daily oral corticosteroids must be on a stable dose for 3 months before Screening Visit 1. 3. Use of one of more additional daily maintenance asthma controller medications according to standard practice of care is required. Use of a stable dose of any additional asthma controller medications must be documented for at least 3 months prior to Screening Visit 1. 6. Pre-BD FEV₁ ≥40% and \<80% (\<90% for participants 12 to 17 years of age) of predicted at Screening Visit 2. 7. Variable airflow obstruction documented with at least one of the following criteria: 1. Bronchodilator reversibility at Screening Visit 2, as evidenced by ≥12% and ≥200 mL improvement in FEV₁, 15 to 30 minutes following inhalation of 400 µg (four puffs) of albuterol/salbutamol (≥12% and ≥160 mL for ages 12 to 17). Participants who do not meet the bronchodilator reversibility inclusion criterion but have ≥10% and ≥160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening period, at an unscheduled visit at least 7 days prior to baseline. 2. Bronchodilator reversibility, using the criteria above, documented in the past 24 months prior to Screening Visit 1 or during Screening. 3. Peak flow variation of ≥20% over a 2-week period, documented in the past 24 months prior to Screening Visit 1 or during Screening. 4. Airflow variability in clinic FEV₁ ≥20% between two consecutive clinic visits, documented in the past 24 months prior to Screening Visit 1. 5. Airway hyperresponsiveness (provocative concentration causing a 20% fall in FEV₁ of methacholine \<8 mg/mL or other clinically relevant bronchoprovocation testing) documented in the past 24 months prior to Screening Visit 1 or during Screening. 8. ACQ-6 ≥1.5 at Screening Visit 2. 9. Documented history of at least two asthma exacerbations requiring treatment with systemic corticosteroids (intramuscular, intravenous, or oral) within the past 12-month period prior to Screening Visit 1. General medical history 10. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Screening and Baseline visits. 11. WOCBP must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit: 1. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective Intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive. * Or 2. Two protocol acceptable methods of contraception in tandem. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for ≥12 months prior to the planned date of the Baseline Visit without an alternative medical cause. The following age specific requirements apply: 3. Women \<50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range. 4. Women ≥50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment. Exclusion Criteria: Asthma-related criteria 1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids) at any time from 4 weeks prior to Screening Visit 1. Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening Visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status. 2. Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, hypereosinophilic syndrome, or lung diseases (eg, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis). 3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1. Prohibited medications/procedures 4. Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long-acting anti-IL-5) in the past 12 months. 5. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab. 6. Treatment with pramipexole (Mirapex®) within 30 days of Baseline. 7. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1. 8. Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the coming year. General medical history 9. Weight \<40 kg at Screening Visit 1. 10. Current smoking within 12 months prior to Screening Visit 1 or a smoking history of \>10 pack-years. Smoking includes tobacco, vaping, and/or marijuana use. 11. Known or suspected alcohol or drug abuse 12. Uncontrolled severe hypertension: systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg prior to Baseline Visit despite anti-hypertensive therapy. 13. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 5 years prior to Baseline Visit. 14. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C. 15. A helminth parasitic infection diagnosed within 24 weeks prior Screening Visit 1 that has not been treated with or has failed to respond to standard of care (SoC) therapy. 16. Medical or other condition likely to interfere with participant's ability to undergo study procedures, adhere to visit schedule, or comply with study requirements. 17. Known or suspected noncompliance with medication. 18. Unwillingness or inability to follow the procedures outlined in the protocol. Clinical safety labs 19. Absolute neutrophil count \<2.000x10⁹/L at screening at Screening Visit 1 or Screening Visit 2. 20. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m² at Screening Visit 2 (using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula \[Levey et al, 2009\] for age ≥18 years at screening; using the Bedside Schwartz \[Schwartz and Work, 2009\] eGFR formula for age \<18). 21. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \>3x the upper limit of normal (ULN), or total bilirubin \>2x ULN at Screening Visit 2 confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart. Cardiac safety 22. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction \<25%. 23. History of major adverse cardiovascular event (MACE) within 3 months prior to the Baseline Visit. 24. History of cardiac arrhythmia within 3 months prior to Baseline Visit that is not controlled by medication or via ablation. 25. History of long QT syndrome. 26. Corrected QT interval by Fridericia (QTcF) interval \>450 ms for males and \>470 ms for females at Screening Visit 2 or QTcF ≥480 ms for participants with bundle branch block. 27. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening Visit 2, including heart rate \<45 beats per minute (bpm) or \>100 bpm. Pregnancy/Lactation 28. Pregnant women or women breastfeeding. 29. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide). 30. Allergy or hypersensitivity to dexpramipexole or any of its components.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic asthma asthma pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma Asthma; eosinophilic Eosinophilic asthma

Contacts and locations

Locations

Research Site -30051-023

Arequipa, 04017, Peru
Research Site -30051-028

Lima, 15072, Peru
Research Site -30054-043

Buenos Aires, Cl426ABP, Argentina
Research Site 20081-010

Kanazawa, 920-8650, Japan
Research Site 20082-028

Seoul, 05278, South Korea
Research Site 30001-010

Little Rock, Arkansas, 72212, United States
Research Site 30001-082

Miami, Florida, 33179, United States
Research Site 30001-090

Austin, Texas, 78726, United States
Research Site 30001-238

San Antonio, Texas, 78258, United States
Research Site 30001-286

Lafayette, Louisiana, 70508, United States
Research Site 30001-287

Mobile, Alabama, 36608, United States
Research Site 30001-288

Miami, Florida, 33165, United States
Research Site 30001-291

Jacksonville, Florida, 32216, United States
Research Site 30001-293

Orlando, Florida, 32819, United States
Research Site 30001-295

McKinney, Texas, 75069, United States
Research Site 30001-297

Pearland, Texas, 77584, United States
Research Site 30001-299

Houston, Texas, 77063, United States
Research Site 30001-300

Schenectady, New York, 12304, United States
Research Site 30001-301

Naples, Florida, 34103, United States
Research Site 30001-304

Valencia, California, 91355, United States
Research Site 30001-305

Valencia, California, 97355, United States
Research Site 30001-310

Miami, Florida, 33165, United States
Research Site 30001-311

Miami, Florida, 33144, United States
Research Site 30001-312

Pembroke Pines, Florida, 33026, United States
Research Site 30001-313

Marrero, Louisiana, 70072, United States
Research Site 30001-315

Katy, Texas, 77494, United States
Research Site 30001-318

Maitland, Florida, 32751, United States
Research Site 30001-319

Viera, Florida, 32940, United States
Research Site 30001-322

Surprise, Arizona, 85378, United States
Research Site 30001-327

Philadelphia, Pennsylvania, 19140, United States
Research Site 30001-328

Maywood, Illinois, 60153, United States
Research Site 30001-329

Miami, Florida, 33165, United States
Research Site 30001-331

Orlando, Florida, 32807, United States
Research Site 30001-333

Pleasant View, Utah, 84404, United States
Research Site 30001-334

Allen, Texas, 60607, United States
Research Site 30001-335

Sugar Land, Texas, 77479, United States
Research Site 30001-345

Vega Baja, 00694, Puerto Rico
Research Site 30001-347

Louisville, Kentucky, 40202, United States
Research Site 30001-348

Ocala, Florida, 34471, United States
Research Site 30001-352

Zachary, Louisiana, 70791, United States
Research Site 30001-362

Laguna Niguel, California, 92677, United States
Research Site 30001-363

Edison, New Jersey, 08817, United States
Research Site 30001-364

Memphis, Tennessee, 38105, United States
Research Site 30001-366

Lilburn, Georgia, 30047, United States
Research Site 30001-372

Warren, Michigan, 48088, United States
Research Site 30001-373

Mesquite, Texas, 75150, United States
Research Site 30001-377

San Antonio, Texas, 78258, United States
Research Site 30001-383

San Juan, 00918, Puerto Rico
Research Site 30001-398

Charlotte, North Carolina, 28277, United States
Research Site 30001-406

Rochester, Minnesota, 55905, United States
Research Site 30001-413

Cleveland, Ohio, 44106, United States
Research Site 30001-414

Annapolis, Maryland, 37067, United States
Research Site 30001-414

Franklin, Tennessee, 37067, United States
Research Site 30001-415

Dallas, Texas, 75246, United States
Research Site 30001-421

Mankato, Minnesota, 56001, United States
Research Site 30001-429

Plantation, Florida, 33317, United States
Research Site 30001-434

San Diego, California, 92123, United States
Research Site 30001-437

Alexandria, Louisiana, 71303, United States
Research Site 30001-439

Rocky Mount, North Carolina, 27804, United States
Research Site 30001-442

Southfield, Michigan, 48034, United States
Research Site 30001-452

Dunwoody, Georgia, 30350, United States
Research Site 30001-455

New York, New York, 10016, United States
Research Site 30001-458

Tucson, Arizona, 85724, United States
Research Site 30001-462

Peoria, Arizona, 85381, United States
Research Site 30001-472

Farmington Hills, Michigan, 48336, United States
Research Site 30001-474

Massena, New York, 13662, United States
Research Site 30001-481

Nederland, Texas, 71627, United States
Research Site 30001-483

East Point, Georgia, 30344, United States
Research Site 30001-484

Santa Monica, California, 90424, United States
Research Site 30001-485

Inglewood, California, 96410, United States
Research Site 30001-487

Chandler, Arizona, 85224, United States
Research Site 30001-489

Pasadena, California, 91105, United States
Research Site 30001-495

Columbus, Ohio, 43235, United States
Research Site 30001-497

Los Angeles, California, 90017, United States
Research Site 30001-499

Hamilton, New Jersey, 08619, United States
Research Site 30001-500

Northridge, California, 91324, United States
Research Site 30001-501

San Diego, California, 92120, United States
Research Site 30001-502

Canoga Park, California, 91303, United States
Research Site 30001-515

West Valley City, Utah, 84120, United States
Research Site 30001-522

North Las Vegas, Nevada, 89030, United States
Research Site 30001-535

Westchester, Illinois, 60154, United States
Research Site 30027-001

Durban, 4000, South Africa
Research Site 30027-004

Pretoria, 0002, South Africa
Research Site 30027-007

Durban, 3630, South Africa
Research Site 30027-008

KwaZulu, 4092, South Africa
Research Site 30027-009

Cape Town, 7530, South Africa
Research Site 30027-010

Durban, 4450, South Africa
Research Site 30027-011

Cape Town, 7570, South Africa
Research Site 30027-012

Cape Town, 7700, South Africa
Research Site 30027-013

Benoni, 1501, South Africa
Research Site 30027-014

Durban, 4091, South Africa
Research Site 30027-015

Thabazimbi, 0380, South Africa
Research Site 30027-017

Welkom, 9460, South Africa
Research Site 30027-018

Vereeniging, 1935, South Africa
Research Site 30027-019

Pretoria, 0204, South Africa
Research Site 30027-021

Cape Town, 7700, South Africa
Research Site 30027-023

Durban, 4301, South Africa
Research Site 30027-026

Johannesburg, 2193, South Africa
Research Site 30027-029

Polokwane, 0699, South Africa
Research Site 30027-030

Johannesburg, 1827, South Africa
Research Site 30027-031

Krugersdorp, 1739, South Africa
Research Site 30027-032

Plettenberg Bay, 6600, South Africa
Research Site 30030-024

Istanbul, 34020, Turkey (Türkiye)
Research Site 30033-001

Marseille, 13003, France
Research Site 30033-002

Lyon, 69317, France
Research Site 30033-003

Paris, 75018, France
Research Site 30033-004

Saint-Herblain, 44800, France
Research Site 30033-005

Grenoble, 38043, France
Research Site 30033-006

Marseille, 13015, France
Research Site 30033-007

Montpellier, 34295, France
Research Site 30033-012

Cholet, 49300, France
Research Site 30033-013

Libourne, 33500, France
Research Site 30033-014

Lille, 59037, France
Research Site 30033-015

Reims, 51100, France
Research Site 30033-018

Strasbourg, 67091, France
Research Site 30034-011

Barcelona, 08017, Spain
Research Site 30034-013

Barcelona, 08036, Spain
Research Site 30034-021

Lugo, 27003, Spain
Research Site 30034-037

Madrid, 28046, Spain
Research Site 30034-041

Vigo, 36211, Spain
Research Site 30034-043

Valencia, 46017, Spain
Research Site 30034-045

Madrid, 28046, Spain
Research Site 30034-046

A Coruña, 15006, Spain
Research Site 30034-049

Barcelona, 08025, Spain
Research Site 30034-050

Santander, 39008, Spain
Research Site 30034-052

A Coruña, 15706, Spain
Research Site 30034-053

Madrid, 28040, Spain
Research Site 30036-001

Budapest, 1122, Hungary
Research Site 30036-005

Balassagyarmat, 2660, Hungary
Research Site 30036-006

Szeged, 6720, Hungary
Research Site 30036-013

Gödöllő, 2100, Hungary
Research Site 30036-014

Debrecen, 4027, Hungary
Research Site 30036-017

Edelény, 3780, Hungary
Research Site 30036-018

Szigetvár, 7900, Hungary
Research Site 30039-002

Padova, 35128, Italy
Research Site 30039-004

Bergamo, 24127, Italy
Research Site 30039-011

Roma, 00168, Italy
Research Site 30039-012

Ferrara, 44124, Italy
Research Site 30039-013

Naples, 80131, Italy
Research Site 30039-017

Reggio Emilia, 42123, Italy
Research Site 30039-020

Genova, 16132, Italy
Research Site 30043-001

Weiz, 1090, Austria
Research Site 30043-012

Vienna, 1130, Austria
Research Site 30043-013

Salzburg, 5020, Austria
Research Site 30044-025

Sheffield, S25FX, United Kingdom
Research Site 30044-027

Glasgow, G20 7BE, United Kingdom
Research Site 30044-039

Leicester, LE3 9QP, United Kingdom
Research Site 30044-059

High Wycombe, HP11 2QW, United Kingdom
Research Site 30049-004

Cottbus, 03050, Germany
Research Site 30049-005

Berlin, 10961, Germany
Research Site 30049-006

Fürstenwalde, 15517, Germany
Research Site 30049-019

Frankfurt, 95606, Germany
Research Site 30049-028

Munich, 81241, Germany
Research Site 30049-029

Witten, 58456, Germany
Research Site 30049-035

Hanover, 30625, Germany
Research Site 30049-038

Magdeburg, 39120, Germany
Research Site 30049-051

Munich, 80539, Germany
Research Site 30049-056

Leipzig, 04357, Germany
Research Site 30049-059

Frankfurt, 63089, Germany
Research Site 30049-060

Berlin, 10717, Germany
Research Site 30049-061

Leipzig, 04275, Germany
Research Site 30049-073

Homburg, 66421, Germany
Research Site 30049-081

Augsburg, 86150, Germany
Research Site 30049-082

Delitzsch, 04509, Germany
Research Site 30051-017

Lima, 15072, Peru
Research Site 30051-020

Lima, 15046, Peru
Research Site 30051-021

Lima, 15801, Peru
Research Site 30051-022

Lima, 15023, Peru
Research Site 30051-026

Lima, 15023, Peru
Research Site 30052-023

Monterrey, 64718, Mexico
Research Site 30052-024

Guadalajara, Jalisco, 44100, Mexico
Research Site 30052-025

Morelia, Michoacon, 58260, Mexico
Research Site 30052-026

Chihuahua City, 31203, Mexico
Research Site 30052-028

Mexico City, 6700, Mexico
Research Site 30052-030

Durango, 34080, Mexico
Research Site 30052-033

León, 37160, Mexico
Research Site 30054-008

Buenos Aires, C1426ABP, Argentina
Research Site 30054-010

Mendoza, M5500CCG, Argentina
Research Site 30054-012

Buenos Aires, B1900BNN, Argentina
Research Site 30054-015

Buenos Aires, C1121ABE, Argentina
Research Site 30054-021

Buenos Aires, B7600FYK, Argentina
Research Site 30054-024

Buenos Aires, C1425BEN, Argentina
Research Site 30054-026

Buenos Aires, B1824KAJ, Argentina
Research Site 30054-028

Mendoza, M550JIAAJ, Argentina
Research Site 30054-031

Buenos Aires, 4190, Argentina
Research Site 30054-032

Mendoza, M5501GCA, Argentina
Research Site 30054-034

Buenos Aires, B8000JRB, Argentina
Research Site 30054-035

Buenos Aires, 30054-035, Argentina
Research Site 30054-042

Santa Fe, 2128, Argentina
Research Site 30054-044

Buenos Aires, B1878FNR, Argentina
Research Site 30054-045

Buenos Aires, B1646EBJ, Argentina
Research Site 30054-047

Mendoza, 5509, Argentina
Research Site 30054-048

Buenos Aires, 8000, Argentina
Research Site 30054-049

Buenos Aires, B1842, Argentina
Research Site 30054-050

Buenos Aires, B1842, Argentina
Research Site 30054-051

Córdoba, 5000, Argentina
Research Site 30054-052

Córdoba, 5000, Argentina
Research Site 30054-054

Concepción del Uruguay, E3260EPD, Argentina
Research Site 30055-021

Porto Alegre, 90410-000, Brazil
Research Site 30055-025

Salvador, 40060-325, Brazil
Research Site 30055-025

São Paulo, 03164-000, Brazil
Research Site 30055-035

Rio de Janeiro, 22061-080, Brazil
Research Site 30055-036

Curitiba, 808101-00, Brazil
Research Site 30056-005

Temuco, 4781151, Chile
Research Site 30056-006

Santiago, 8330034, Chile
Research Site 30056-007

Santiago, 7500657, Chile
Research Site 30056-009

Curicó, 3341643, Chile
Research Site 30056-010

Santiago, 7630226, Chile
Research Site 30056-011

Santiago, 7510000, Chile
Research Site 30056-012

Santiago, 8389001, Chile
Research Site 30056-013

Santiago, Providencia, 7501126, Chile
Research Site 30056-013

Santiago, 7501126, Chile
Research Site 30056-014

Viña del Mar, 2520598, Chile
Research Site 30082-010

Suwon, 16499, South Korea
Research Site 30082-017

Wŏnju, 26426, South Korea
Research Site 30082-018

Seoul, 03312, South Korea
Research Site 30082-019

Gwangju, 61469, South Korea
Research Site 30082-022

Seoul, 02841, South Korea
Research Site 30086-021

Shanghai, 201299, China
Research Site 30090-002

Yüreğir, 01240, Turkey (Türkiye)
Research Site 30090-008

Ankara, 06620, Turkey (Türkiye)
Research Site 30090-009

Ankara, 06930, Turkey (Türkiye)
Research Site 30090-010

Nilufer, 16059, Turkey (Türkiye)
Research Site 30090-011

Istanbul, 34844, Turkey (Türkiye)
Research Site 30090-012

Izmir, 35170, Turkey (Türkiye)
Research Site 30090-013

Mersin, 33110, Turkey (Türkiye)
Research Site 30090-016

Çanakkale, 17020, Turkey (Türkiye)
Research Site 30090-017

Alanya, 07400, Turkey (Türkiye)
Research Site 30090-018

Ankara, 06230, Turkey (Türkiye)
Research Site 30090-019

Bornova, 35100, Turkey (Türkiye)
Research Site 30090-020

Istanbul, 34020, Turkey (Türkiye)
Research Site 30090-021

Ankara, 06230, Turkey (Türkiye)
Research Site 30090-022

Tekirdağ, 59100, Turkey (Türkiye)
Research Site 30090-026

Istanbul, 34750, Turkey (Türkiye)
Research Site 30090-027

Gaziantep, 27410, Turkey (Türkiye)
Research Site 30090-029

Antalya, 07070, Turkey (Türkiye)
Research Site 30091-001

Surat, Gujarat, 395006, India
Research Site 30091-004

Nagpur, Maharashta, 440010, India
Research Site 30091-006

Ahmedabad, Gujarat, 382345, India
Research Site 30091-010

Ahmedabad, Gujarat, 382350, India
Research Site 30091-011

Himmatnagar, Gujarat, 383001, India
Research Site 30091-018

Jaipur, Rajasthan, 302039, India
Research Site 30091-021

Kanpur, 208002, India
Research Site 30091-023

Nagpur, Maharashta, 440010, India
Research Site 30091-024

Rohtak, Haryana, 124001, India
Research Site 30091-033

Pune, Maharashta, 411057, India
Research Site 30091-043

Aurangabad, Maharashta, 431001, India
Research Site 30370-002

Vilnius, 06256, Lithuania
Research Site 30370-016

Kaunas, 50161, Lithuania
Research Site 30370-017

Klaipėda, 92231, Lithuania
Research Site 30380-002

Chernivtsi, 58001, Ukraine
Research Site 30380-011

Kyiv, 03057, Ukraine
Research Site 30385-002

Zagreb, 10000, Croatia
Research Site 30385-007

Zagreb, 10000, Croatia
Research Site 30385-008

Zadar, 23000, Croatia
Research Site 30420-003

Jindřichův Hradec, 37 701, Czechia
Research Site 30420-007

Lovosice, 41 002, Czechia
Research Site 30420-009

Teplice, 41 501, Czechia
Research Site 30420-010

Strakonice, 38 601, Czechia
Research Site 30420-012

Brno, 62 500, Czechia
Research Site 30420-014

Olomouc, 77 900, Czechia
Research Site 30420-018

Brno, 61 800, Czechia
Research Site 30787-388

Rio Piedras, 00918, Puerto Rico
Research Site 30787-405

San Juan, 00918, Puerto Rico
Research Site 30886-003

Taipei, 112, Taiwan
Research Site 30886-004

New Taipei City, 220, Taiwan
Research Site 30886-005

Taichung, 404327, Taiwan
Research Site 30886-006

New Taipei City, 23561, Taiwan
Research Site 30886-007

Taichung, 40705, Taiwan
Research Site 30886-008

Taipei, 11031, Taiwan
Research Site 30886-009

Taipei, 112, Taiwan
Research Site 30886-010

Taipei, 100, Taiwan
Research Site 30886-011

Tainan, Taiwan
Research Site 30886-013

Douliu, 640, Taiwan
Research Site 30972-001

Jerusalem, 9112026851, Israel
Research Site 30972-005

Sha‘ar Ha‘Aliya, 3109601, Israel
Research Site 30972-008

Beersheba, Israel
Research Site 30972-009

Kfar Saba, 4428164, Israel
Research Site 30972-011

Ramat Gan, 5262000, Israel
Research Site 30972-012

Rehovot, 7661041, Israel
Research Site US-30001-369

New York, New York, 10029, United States
Research Site US-30001-418

Frisco, Texas, 75034, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.